News: Monoclonal antibody prevents malaria in small NIH trial https://t.co/tDZjkfQUKC — NIH (@NIH) August 11, 2021The only licensed malaria vaccine, Mosquirix, developed by GlaxoSmithKline, is around 30% effective. None of the nine who received CIS43LS developed malaria, compared with five of the six who did not receive the drug. Monoclonal antibodies are manufactured copies of disease-fighting proteins called antibodies. NIH’s latest study is the first to show monoclonal antibodies can prevent malaria. Results of a larger, mid-stage trial being conducted to assess CIS43LS during a six-month malaria season in Mali are expected in 2022.

Source: Indian Express August 13, 2021 15:00 UTC